[{"id":"ebc393d7-e583-45ba-8ae9-46feb62c3abf","acronym":"","url":"https://clinicaltrials.gov/study/NCT05376878","created_at":"2022-05-17T12:54:20.623Z","updated_at":"2025-02-25T14:08:52.333Z","phase":"Phase 4","brief_title":"An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis","source_id_and_acronym":"NCT05376878","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Trazimera (trastuzumab-qyyp)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 12/21/2022","start_date":" 12/21/2022","primary_txt":" Primary completion: 02/25/2026","primary_completion_date":" 02/25/2026","study_txt":" Completion: 02/25/2026","study_completion_date":" 02/25/2026","last_update_posted":"2025-02-18"},{"id":"18460073-b219-4680-b839-36cecdb58964","acronym":"CALGB-40601","url":"https://clinicaltrials.gov/study/NCT00770809","created_at":"2021-01-17T17:29:01.763Z","updated_at":"2025-02-25T16:36:00.390Z","phase":"Phase 3","brief_title":"Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery","source_id_and_acronym":"NCT00770809 - CALGB-40601","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • lapatinib • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • GB221 (coprelotamab) • SIBP-01 (trastuzumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 305","initiation":"Initiation: 12/01/2008","start_date":" 12/01/2008","primary_txt":" Primary completion: 01/31/2014","primary_completion_date":" 01/31/2014","study_txt":" Completion: 07/10/2025","study_completion_date":" 07/10/2025","last_update_posted":"2025-02-06"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"b1b80856-36d7-4b3b-b80b-159943ef72f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04329065","created_at":"2021-01-18T20:58:01.125Z","updated_at":"2025-02-25T16:44:52.494Z","phase":"Phase 2","brief_title":"Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer","source_id_and_acronym":"NCT04329065","lead_sponsor":"University of Washington","biomarkers":" HER-2 • ER • PGR • CD4","pipe":" | ","alterations":" ER negative • PGR negative","tags":["HER-2 • ER • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • EG1206A (pertuzumab biosimilar) • SIBP-01 (trastuzumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 04/20/2022","start_date":" 04/20/2022","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-06"},{"id":"c044dc83-7f98-4b8c-81bf-f2a99c8a914c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00769379","created_at":"2021-01-18T02:54:21.132Z","updated_at":"2025-02-25T16:35:59.903Z","phase":"Phase 3","brief_title":"Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy","source_id_and_acronym":"NCT00769379","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive • HR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • GB221 (coprelotamab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2014","initiation":"Initiation: 11/10/2008","start_date":" 11/10/2008","primary_txt":" Primary completion: 12/31/2019","primary_completion_date":" 12/31/2019","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-06"},{"id":"d258ffb1-712c-47d0-9e3b-45ef523e42fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04181333","created_at":"2021-01-18T20:23:20.534Z","updated_at":"2025-02-25T17:36:28.904Z","phase":"","brief_title":"Safety and Efficacy of Trastuzumab BS","source_id_and_acronym":"NCT04181333","lead_sponsor":"Pfizer","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Trazimera (trastuzumab-qyyp)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 08/09/2023","start_date":" 08/09/2023","primary_txt":" Primary completion: 02/14/2025","primary_completion_date":" 02/14/2025","study_txt":" Completion: 02/14/2025","study_completion_date":" 02/14/2025","last_update_posted":"2025-01-28"},{"id":"8246cf27-0853-4b25-adbc-f7d54fbbd62d","acronym":"NCI-2016-00570","url":"https://clinicaltrials.gov/study/NCT02827877","created_at":"2021-01-18T13:51:54.989Z","updated_at":"2025-02-25T14:01:03.457Z","phase":"Phase 2","brief_title":"Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer","source_id_and_acronym":"NCT02827877 - NCI-2016-00570","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 positive + HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 positive + HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • Trazimera (trastuzumab-qyyp)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 07/15/2016","start_date":" 07/15/2016","primary_txt":" Primary completion: 07/02/2020","primary_completion_date":" 07/02/2020","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-01-24"},{"id":"79433067-e78e-4567-8836-adaaf499b67a","acronym":"SWOG S1613","url":"https://clinicaltrials.gov/study/NCT03365882","created_at":"2021-01-18T16:36:41.796Z","updated_at":"2025-02-25T13:52:26.960Z","phase":"Phase 2","brief_title":"S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT03365882 - SWOG S1613","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" HER-2 • KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • HER-2 amplification • BRAF V600","tags":["HER-2 • KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • HER-2 amplification • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Erbitux (cetuximab) • Perjeta (pertuzumab) • irinotecan • Trazimera (trastuzumab-qyyp)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 11/27/2017","start_date":" 11/27/2017","primary_txt":" Primary completion: 11/01/2022","primary_completion_date":" 11/01/2022","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2025-01-14"},{"id":"257cca5a-c910-4b83-b699-e799dee41eab","acronym":"","url":"https://clinicaltrials.gov/study/NCT03101748","created_at":"2021-01-18T15:16:53.226Z","updated_at":"2025-02-25T13:52:17.471Z","phase":"Phase 1/2","brief_title":"Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer","source_id_and_acronym":"NCT03101748","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • HER-2 negative + HR negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • HER-2 negative + HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide • Herzuma (trastuzumab-pkrb) • daunorubicin • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • GB221 (coprelotamab) • SIBP-01 (trastuzumab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 01/29/2018","start_date":" 01/29/2018","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-12-13"},{"id":"efccfeae-b1d6-4b39-873a-d9182d5a3bf3","acronym":"NRG-BR004","url":"https://clinicaltrials.gov/study/NCT03199885","created_at":"2021-01-18T15:46:49.625Z","updated_at":"2025-02-25T12:26:43.973Z","phase":"Phase 3","brief_title":"Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer","source_id_and_acronym":"NCT03199885 - NRG-BR004","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PGR • IL2","pipe":" | ","alterations":" HER-2 positive","tags":["ER • PGR • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • paclitaxel • docetaxel • Perjeta (pertuzumab) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • Paletan (pertuzumab biosimilar) • EG1206A (pertuzumab biosimilar) • GB221 (coprelotamab) • HS627 (pertuzumab biosimilar) • Pertuvia (pertuzumab biosimilar) • SIBP-01 (trastuzumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 190","initiation":"Initiation: 04/05/2019","start_date":" 04/05/2019","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 05/15/2025","study_completion_date":" 05/15/2025","last_update_posted":"2024-09-26"},{"id":"5455e56f-c7d0-43e1-93b2-556c1632eeb2","acronym":"UCLA l-08","url":"https://clinicaltrials.gov/study/NCT04285671","created_at":"2023-11-26T01:10:15.098Z","updated_at":"2024-07-02T16:34:26.639Z","phase":"Phase 1/2","brief_title":"Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04285671 - UCLA l-08","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" HER-2 • AXL","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • HER-2 expression • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["HER-2 • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • HER-2 expression • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Herzuma (trastuzumab-pkrb) • Trazimera (trastuzumab-qyyp) • Portrazza (necitumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/29/2021","start_date":" 01/29/2021","primary_txt":" Primary completion: 12/02/2025","primary_completion_date":" 12/02/2025","study_txt":" Completion: 12/02/2026","study_completion_date":" 12/02/2026","last_update_posted":"2024-06-13"},{"id":"7400d1d1-c93a-4e3e-a35d-94aa2105cdee","acronym":"","url":"https://clinicaltrials.gov/study/NCT05378464","created_at":"2022-05-18T13:00:43.972Z","updated_at":"2024-07-02T16:34:38.084Z","phase":"Phase 1","brief_title":"Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine \u0026 Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer","source_id_and_acronym":"NCT05378464","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" HER-2 • PGR • CD4","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification • ER positive + PGR positive • PGR positive","tags":["HER-2 • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification • ER positive + PGR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Trazimera (trastuzumab-qyyp) • pepinemab (VX15)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 05/31/2022","start_date":" 05/31/2022","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-06-05"},{"id":"130d64cc-8174-4099-9fdc-c77e00468d6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02003209","created_at":"2021-01-18T09:08:50.149Z","updated_at":"2024-07-02T16:35:02.395Z","phase":"Phase 3","brief_title":"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer","source_id_and_acronym":"NCT02003209","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" TILs","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • goserelin acetate • Herwenda (trastuzumab biosimilar) • Paletan (pertuzumab biosimilar) • EG1206A (pertuzumab biosimilar) • GB221 (coprelotamab) • HS627 (pertuzumab biosimilar) • Pertuvia (pertuzumab biosimilar) • SIBP-01 (trastuzumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 315","initiation":"Initiation: 01/15/2014","start_date":" 01/15/2014","primary_txt":" Primary completion: 10/31/2016","primary_completion_date":" 10/31/2016","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-21"},{"id":"c5f41829-50ce-4b6e-882c-2736b1a86fe9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01275677","created_at":"2021-01-18T05:10:25.363Z","updated_at":"2024-07-02T16:35:02.423Z","phase":"Phase 3","brief_title":"Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer","source_id_and_acronym":"NCT01275677","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • docetaxel • doxorubicin hydrochloride • cyclophosphamide • Herzuma (trastuzumab-pkrb) • daunorubicin • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • GB221 (coprelotamab) • SIBP-01 (trastuzumab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3270","initiation":"Initiation: 01/06/2011","start_date":" 01/06/2011","primary_txt":" Primary completion: 07/31/2017","primary_completion_date":" 07/31/2017","study_txt":" Completion: 07/12/2024","study_completion_date":" 07/12/2024","last_update_posted":"2024-05-21"},{"id":"77303f62-6e39-4d65-a62b-36ab4c8e233e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04266249","created_at":"2021-01-18T20:43:47.844Z","updated_at":"2025-02-25T13:53:10.003Z","phase":"Phase 2","brief_title":"CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy","source_id_and_acronym":"NCT04266249","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • albumin-bound paclitaxel • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 2156","initiation":"Initiation: 03/13/2020","start_date":" 03/13/2020","primary_txt":" Primary completion: 10/31/2026","primary_completion_date":" 10/31/2026","study_txt":" Completion: 12/31/2038","study_completion_date":" 12/31/2038","last_update_posted":"2024-04-18"},{"id":"7ef46664-9a37-4dc4-90b3-36eef7f2d80e","acronym":"SCHOLAR-2","url":"https://clinicaltrials.gov/study/NCT04680442","created_at":"2021-01-19T20:46:32.852Z","updated_at":"2025-02-25T13:53:34.367Z","phase":"Phase 2","brief_title":"Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction","source_id_and_acronym":"NCT04680442 - SCHOLAR-2","lead_sponsor":"Population Health Research Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Herzuma (trastuzumab-pkrb) • Trazimera (trastuzumab-qyyp)"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 07/01/2021","start_date":" 07/01/2021","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-03-15"},{"id":"2980bbee-f00d-4630-9f55-6aacdaeb4026","acronym":"NRG-HN010","url":"https://clinicaltrials.gov/study/NCT05408845","created_at":"2022-06-07T22:00:44.587Z","updated_at":"2024-07-02T16:35:20.570Z","phase":"Phase 2","brief_title":"Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer","source_id_and_acronym":"NCT05408845 - NRG-HN010","lead_sponsor":"NRG Oncology","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • Kadcyla (ado-trastuzumab emtansine) • Trazimera (trastuzumab-qyyp)"],"overall_status":"Recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 09/30/2022","start_date":" 09/30/2022","primary_txt":" Primary completion: 07/31/2028","primary_completion_date":" 07/31/2028","study_txt":" Completion: 07/31/2028","study_completion_date":" 07/31/2028","last_update_posted":"2024-02-07"},{"id":"1d2920ad-7680-4e69-b51f-ddb29e043f61","acronym":"ACT","url":"https://clinicaltrials.gov/study/NCT05238831","created_at":"2023-08-08T16:08:43.868Z","updated_at":"2025-02-25T12:28:40.109Z","phase":"Phase 1","brief_title":"SMMART Adaptive Clinical Treatment (ACT) Trial","source_id_and_acronym":"NCT05238831 - ACT","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" HER-2 • BRCA1 • BRCA2","pipe":" | ","alterations":" HR positive • HER-2 negative • EGFR positive","tags":["HER-2 • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • carboplatin • Rozlytrek (entrectinib) • Alecensa (alectinib) • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • capecitabine • Piqray (alpelisib) • Zejula (niraparib) • albumin-bound paclitaxel • fulvestrant • irinotecan • Halaven (eribulin mesylate) • letrozole • vinorelbine tartrate • Herzuma (trastuzumab-pkrb) • anastrozole • Erivedge (vismodegib) • Trazimera (trastuzumab-qyyp) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • EG1206A (pertuzumab biosimilar)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/30/2023","start_date":" 01/30/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-01-23"},{"id":"c60be604-22ae-4720-aa55-9dec4b384f9a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01750073","created_at":"2023-12-20T18:16:31.039Z","updated_at":"2024-07-02T16:35:25.629Z","phase":"Phase 2","brief_title":"Paclitaxel \u0026 Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer","source_id_and_acronym":"NCT01750073","lead_sponsor":"University of Nebraska","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Trazimera (trastuzumab-qyyp)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 12/07/2012","start_date":" 12/07/2012","primary_txt":" Primary completion: 05/01/2022","primary_completion_date":" 05/01/2022","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2023-12-20"},{"id":"d62c1b12-231e-41f3-9f47-89579c4ab1f5","acronym":"ACCRU-BR-1701","url":"https://clinicaltrials.gov/study/NCT04197687","created_at":"2021-01-18T20:27:24.447Z","updated_at":"2025-02-25T13:53:04.701Z","phase":"Phase 2","brief_title":"TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery","source_id_and_acronym":"NCT04197687 - ACCRU-BR-1701","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • HER-2/neu peptide vaccine • Leukine (sargramostim) • TPIV100"],"overall_status":"Recruiting","enrollment":" Enrollment 480","initiation":"Initiation: 02/20/2020","start_date":" 02/20/2020","primary_txt":" Primary completion: 01/15/2025","primary_completion_date":" 01/15/2025","study_txt":" Completion: 01/15/2025","study_completion_date":" 01/15/2025","last_update_posted":"2023-12-18"},{"id":"6cdd3cff-a8f2-4076-b8fb-2e4bb4de86c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04120246","created_at":"2021-01-18T20:08:08.496Z","updated_at":"2024-07-02T16:35:26.492Z","phase":"Phase 1","brief_title":"Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer","source_id_and_acronym":"NCT04120246","lead_sponsor":"Veana Therapeutics","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • GB221 (coprelotamab) • Vimo (alpha-tocopheroloxyacetic acid)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 04/08/2020","start_date":" 04/08/2020","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2023-12-12"},{"id":"5b38253f-bfcb-468a-a302-a0f7d2c95576","acronym":"ACCRU-GI-2003","url":"https://clinicaltrials.gov/study/NCT05356897","created_at":"2022-05-02T11:56:49.270Z","updated_at":"2024-07-02T16:35:33.591Z","phase":"Phase 2","brief_title":"Tucatinib Combined With Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study","source_id_and_acronym":"NCT05356897 - ACCRU-GI-2003","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" HER-2 • KRAS • BRAF • PIK3CA • NRAS • MSI","pipe":" | ","alterations":" MSI-H/dMMR • BRAF mutation • HER-2 amplification • PIK3CA mutation • BRAF V600","tags":["HER-2 • KRAS • BRAF • PIK3CA • NRAS • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • BRAF mutation • HER-2 amplification • PIK3CA mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tukysa (tucatinib) • Lonsurf (trifluridine/tipiracil) • Trazimera (trastuzumab-qyyp)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/30/2023","start_date":" 11/30/2023","primary_txt":" Primary completion: 05/30/2024","primary_completion_date":" 05/30/2024","study_txt":" Completion: 05/30/2029","study_completion_date":" 05/30/2029","last_update_posted":"2023-10-13"},{"id":"1c68e673-30b8-48a7-84c9-a395e96c56ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT02654119","created_at":"2021-01-18T12:56:02.584Z","updated_at":"2024-07-02T16:35:33.848Z","phase":"Phase 2","brief_title":"Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery","source_id_and_acronym":"NCT02654119","lead_sponsor":"University of Nebraska","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • cyclophosphamide • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/11/2015","start_date":" 12/11/2015","primary_txt":" Primary completion: 11/20/2025","primary_completion_date":" 11/20/2025","study_txt":" Completion: 11/20/2026","study_completion_date":" 11/20/2026","last_update_posted":"2023-10-12"},{"id":"50582c14-86ea-44cb-8fc7-88d457745d55","acronym":"","url":"https://clinicaltrials.gov/study/NCT01196390","created_at":"2021-01-17T17:23:25.790Z","updated_at":"2024-07-02T16:35:37.856Z","phase":"Phase 3","brief_title":"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer","source_id_and_acronym":"NCT01196390","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • paclitaxel • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • GB221 (coprelotamab) • SIBP-01 (trastuzumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 203","initiation":"Initiation: 02/14/2011","start_date":" 02/14/2011","primary_txt":" Primary completion: 12/23/2019","primary_completion_date":" 12/23/2019","study_txt":" Completion: 08/15/2023","study_completion_date":" 08/15/2023","last_update_posted":"2023-09-07"}]